Cancer Treatment: The Critical Factors
In order to derive the greatest potential benefit from any cancer treatment regimen, both patients and physicians must respect and adapt to the complex and multidimensional nature of each individual's unique cancer. Sadly, the mainstream medical establishment treats the majority of cancer cases with a "one size fits all" strategy that may deprive many patients of a greater chance of successful treatment.
Implementing strategies to address each of the ten critical factors of cancer treatment identified in this Life Extension protocol provides an evidenced based approach that will:
- Aid physicians in determining which medical therapies are most likely to be effective for each individual's unique cancer;
- Pharmacogenomically and nutrigenomically target multiple biochemical pathways known to be aberrant in many cancers;
- Provide a more thorough prognostic analysis that can help physicians make informed decisions about how aggressive treatment should be, and to properly inform their patients about the state of their health, and;
- Educate patients about some potential side effects associated with conventional cancer treatment options, and what they can do to minimize risk.
In this protocol, Life Extension will discuss the following ten critical steps that may increase the likelihood of a successful outcome in the treatment of many cancers:
- Evaluating the molecular biology of the tumor cell population
- Analyzing the patient's living tumor cells to determine sensitivity or resistance to chemotherapy
- Circulating tumor cell (CTC) testing
- Inhibiting the cyclooxygenase enzymes (COX-1 and COX-2)
- Suppressing Ras oncogene expression
- Correcting coagulation abnormalities
- Maintaining bone integrity
- Inhibiting angiogenesis
- Inhibiting the 5-lipoxygenase (5-LOX) enzyme
- Inhibiting cancer metastasis
Of critical importance to treatment-naïve patients is implementing as many of these ten critical steps as can safely be done concurrently with conventional therapy. In newly diagnosed patients who have not yet been treated, the objective is to eradicate the primary tumor and metastatic cells with a multi-pronged "first strike therapy" so that residual tumor cells are not given an opportunity to evolve survival mechanisms that make them resistant to further treatments.